On June 13, 2026 Principal, Ms. Pauli Wongspoke at the “Entrepreneurial Workshop,” an elective course under the Master of Technology Entrepreneurship program at the Hong Kong Polytechnic University (PolyU).

Invited as the course's external expert, Pauli shared her extensive expertise with an audience of approximately 35 aspiring tech entrepreneurs, primarily from mainland China.

The interactive session focused on the highly relevant topic “如何运用专利构建科技企业的护城河” (How to Use Patents to Build a Moat for Tech Enterprises).” Drawing from her deep background in patent drafting and global prosecution, Pauli provided real-world case studies, strategic advice, and practical insights on how startups can effectively leverage intellectual property as a defensive moat to protect their tech innovations and scale their businesses safely.

我們過去活動

Recommended Insights

How Far Can an Employer Reach to Own Employee-made “Service Inventions”?

2020年7月30日
2019 China’s Top 50 Representative IP Cases Shenzhen Weibang Technology Co. Ltd v. Li Jianyi & Shenzhen Yuancheng Intelligence Equipment Co. Ltd (2019最高法民申6342号) Each year in China there are hundreds of disputes over patent ownership.  A significant part of them are related to “Service Inventions”, which are defined in Article 6 of the Chinese Patent […]

How will Civil Cases Work under the Patent Linkage Provision in the New Chinese Patent Law?

2020年11月20日
The Supreme People’s Court has just issued draft regulations for comment regarding how new Article 76 will work in conjunction with civil procedure law. The period to submit comments ends December 14, 2020, and the final version will come into force June 1, 2021, together with the new Chinese Patent Law. The Backdrop: New Chinese […]

Connecting the Dots: China’s Evolving Standard for Numerical Sub-Range Amendments

2026年7月22日
Managing global pharmaceutical or chemical portfolios requires navigating China’s notoriously rigid standards on the "same subject matter" requirement for priority and claim amendments. A recent invalidation decision (No. 588094) issued by the China National Intellectual Property Administration (CNIPA) concerning a pharmaceutical patent provides clarity on how numerical ranges and later added experimental data are evaluated […]
Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

2020年7月14日
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
Top crossarrow-right